Inventor · disambiguated record
Mark Leo Michaels
Also filed as: MICHAELS MARK · MICHAELS MARK L · MICHAELS MARK LEO
26 granted patents·23 pending applications·672 citations·filing 1996–2024
97Inventor score
Top patents by PatentIndex Score
49 records- 0198US8642546B2FGF21 mutant fusion polypeptides and uses thereofBELOUSKI EDWARD JOHN·Filed 2011·Granted Feb 4, 2014·64 cites·11 claims
- 0298US8410051B2FGF21 mutants and uses thereofBELOUSKI EDWARD JOHN·Filed 2011·Granted Apr 2, 2013·63 cites·21 claims
- 0398US8361963B2Uses of FGF21 polypeptides comprising two or more mutationsAMGEN INC·Filed 2011·Granted Jan 29, 2013·64 cites·4 claims
- 0498US8034770B2FGF21 polypeptides comprising two or more mutationsAMGEN INC·Filed 2009·Granted Oct 11, 2011·63 cites·15 claims
- 0597US8835385B2FGF21 polypeptides comprising two or more mutations and uses thereofBELOUSKI EDWARD JOHN·Filed 2012·Granted Sep 16, 2014·48 cites·26 claims
- 0697US8795985B2FGF 21 polypeptides comprising two or more mutations and uses thereofBELOUSKI EDWARD JOHN·Filed 2012·Granted Aug 5, 2014·48 cites·18 claims
- 0797US8618053B2FGF21 mutants multimers and uses thereofBELOUSKI EDWARD JOHN·Filed 2012·Granted Dec 31, 2013·45 cites·18 claims
- 0897US8188040B2FGF21 mutants and uses thereofBELOUSKI EDWARD JOHN·Filed 2010·Granted May 29, 2012·59 cites·21 claims
- 0996US8410043B2Stabilized activin IIB receptor polypeptides and uses thereofSUN JEONGHOON·Filed 2009·Granted Apr 2, 2013·54 cites·15 claims
- 1094US9273114B2Stabilized receptor polypeptides and uses thereofAMGEN·Filed 2013·Granted Mar 1, 2016·19 cites·31 claims
- 1194US9273106B2FGF mutants with reduced proteolysis and aggregationAMGEN INC·Filed 2013·Granted Mar 1, 2016·9 cites·21 claims
- 1293US11072640B2Methods of treating non-alcoholic steatohepatitis using FGF21 mutantsAMGEN INC·Filed 2018·Granted Jul 27, 2021·3 cites·12 claims
- 1393US10308704B2Isolated nucleic acid molecules encoding stabilized receptor polypeptides and uses thereofAMGEN INC·Filed 2016·Granted Jun 4, 2019·12 cites·8 claims
- 1493US10011642B2Methods of treating of diabetes and obesity using FGF21 mutantsAMGEN INC·Filed 2016·Granted Jul 3, 2018·4 cites·28 claims
- 1591US2025136653A1FGF21 Mutants and Uses ThereofAMGEN INC·Filed 2024·Application pending·0 cites
- 1690US6096865AMutants of the green fluorescent protein having improved fluorescent properties at 37°AMGEN INC·Filed 1996·Granted Aug 1, 2000·79 cites·6 claims
- 1790US2024076333A1FGF21 Mutants and Uses ThereofAMGEN INC·Filed 2023·Application pending·0 cites
- 1888US9493530B2FGF21 mutants comprising a mutation at position 98, 171 and/or 180AMGEN INC·Filed 2014·Granted Nov 15, 2016·10 cites·25 claims
- 1984US9517264B2Human FGF receptor and β-Klotho binding proteinsFACHINI ROGER·Filed 2011·Granted Dec 13, 2016·19 cites·41 claims
- 2084US2023295267A1Stabilized receptor polypeptides and uses thereofAMGEN INC·Filed 2023·Application pending·0 cites
- 2182US11753475B2Bispecific-Fc moleculesAMGEN INC·Filed 2018·Granted Sep 12, 2023·1 cites·8 claims
- 2281US2024150448A1Pac1 antibodies and uses thereofAMGEN INC·Filed 2023·Application pending·0 cites
- 2380US11840558B2Methods of treating non-alcoholic steatohepatitis using FGF21 mutantsAMGEN INC·Filed 2021·Granted Dec 12, 2023·0 cites·23 claims
- 2480US9279013B2FGF-21 mutants comprising polyethylene glycol and uses thereofWALKER KENNETH W·Filed 2009·Granted Mar 8, 2016·3 cites·53 claims
- 2579US2023212297A1Bispecific fc moleculesAMGEN INC·Filed 2022·Application pending·0 cites
- 2679US2024010708A1Variants of tissue inhibitor of metalloproteinase type three (timp-3), compositions and methodsAMGEN INC·Filed 2023·Application pending·0 cites
- 2776US11634502B2Heterodimeric bispecific antibodiesAMGEN INC·Filed 2014·Granted Apr 25, 2023·2 cites·24 claims
- 2874US9688756B2Variant Fc-polypeptides with enhanced binding to the neonatal Fc receptorAMGEN INC·Filed 2012·Granted Jun 27, 2017·3 cites·16 claims
- 2973US2023055407A1V-c-fc-v-c antibodyAMGEN INC·Filed 2022·Application pending·0 cites
- 3072US11685770B2Stabilized receptor polypeptides and uses thereofAMGEN INC·Filed 2019·Granted Jun 27, 2023·0 cites·6 claims
- 3172US2023077648A1Heterodimeric Bispecific AntibodiesAMGEN INC·Filed 2022·Application pending·0 cites
- 3267US2020071425A1Heterodimeric Bispecific AntibodiesAMGEN INC·Filed 2019·Application pending·0 cites
- 3367US2023212318A1Protease-activatable bispecific proteinsAMGEN INC·Filed 2022·Application pending·0 cites
- 3463US10189890B2Variants of tissue inhibitor of metalloproteinase type three (TIMP-3), compositions and methodsAMGEN INC·Filed 2014·Granted Jan 29, 2019·0 cites·6 claims
- 3563US2016257748A1V-c-fc-v-c antibodyAMGEN INC·Filed 2014·Application pending·0 cites
- 3663US2020040075A1V-c-fc-v-c antibodyAMGEN INC·Filed 2019·Application pending·0 cites
- 3762US2019002568A1Bispecific fc moleculesAMGEN INC·Filed 2018·Application pending·0 cites
- 3862US2016145340A1Bispecific-fc moleculesAMGEN INC·Filed 2014·Application pending·0 cites
- 3962US2014302037A1BISPECIFIC-Fc MOLECULESAMGEN INC·Filed 2014·Application pending·0 cites
- 4060US2014308285A1Heterodimeric bispecific antibodiesAMGEN INC·Filed 2014·Application pending·0 cites
- 4159US12435149B2Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (GIPR) in combination with GLP-1 agonistsAMGEN INC·Filed 2018·Granted Oct 7, 2025·0 cites·49 claims
- 4257US2019085054A1Variants of tissue inhibitor of metalloproteinase type three (timp-3), compositions and methodsAMGEN INC·Filed 2018·Application pending·0 cites
- 4355US9708375B2Inhibitory polypeptides specific to WNT inhibitorsAMGEN INC·Filed 2014·Granted Jul 18, 2017·0 cites·10 claims
- 4455US2022402985A1ENGINEERED NRG-1 VARIANTS WITH IMPROVED SELECTIVITY TOWARD ErbB4 BUT NOT AGAINST ErbB3AMGEN INC·Filed 2022·Application pending·0 cites
- 4549US2022363770A1Anti-cgrp receptor/anti-pac1 receptor bispecific antigen binding proteinsAMGEN INC·Filed 2020·Application pending·0 cites
- 4648US2016032014A1Human antigen binding proteins that bind to proprotein convertase subtilisin kexin type 9AMGEN INC·Filed 2014·Application pending·0 cites
- 4744US2016244497A1Fgf21 mutants and uses thereofAMGEN INC·Filed 2016·Application pending·0 cites
- 4844US2012052069A1Fgf21 mutants and uses thereofBELOUSKI EDWARD JOHN·Filed 2010·Application pending·0 cites
- 4942US2017247476A1Protease-activatable bispecific proteinsAMGEN INC·Filed 2015·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Mark Leo Michaels files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →